UK-based law firm Olswang, a specialist in the areas of biosciences, telecommunications, media and technology, says that it has become the first such company in the UK to offer a full bioscience service capability following the appointment of Robert Stephen. Dr Stephen, a qualified European patent attorney and chartered UK patent agent, joins the company from GlaxoSmithKline's intellectual property department.
Olswang went on to say that Dr Stephen's appointment expands its bioscience and IP groups to encompass the filing and prosecution of patents, a service that is not currently offered by any other UK law firm, the company noted.
It added that, in addition to its work in the field of IP, patents and pharmaceutical trade marks, it has been involved in the initial public offerings and investment activities undertaken by several leading bioscience companies. These include: the Phoqus group's L45.0 million ($57.3 million) IPO; Domantis' third round of financing, which raised $29.0 million; and the sale of Zeneus Holdings to US neurological specialist Cephalon, for approximately L207.0 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze